Recent Events - The control change plan has been terminated as of January 7, 2026, due to the failure of the controlling shareholder and the counterparty to reach an agreement, leading to stock resumption and subsequent price fluctuations. This matter is not expected to have a significant adverse impact on the company's operations, which remain normal [1]. Performance Overview - For the period from January to September 2025, the company achieved a revenue of 299 million yuan, representing a year-on-year growth of 2.74%. The net profit attributable to shareholders was 32.67 million yuan, reflecting a year-on-year increase of 36.41%. The company emphasized its core business in small molecule generic drugs, with project applications and approvals ranking among the industry leaders [2]. Stock Performance - As of February 13, 2026, the stock price of the company was 9.32 yuan per share, with a total market capitalization of 3.584 billion yuan. The stock has seen a cumulative decline of 23.86% this year, although it has increased by 1.53% in the last five trading days. On that day, there was a net inflow of 6.07 million yuan in principal funds, with a turnover rate of 0.98%. The company has appeared on the stock leaderboard four times this year, with the most recent occurrence on January 13 [3]. Company Status - In April 2025, the indirect controlling shareholder, Hualing Industrial Trade, was changed to a state-owned enterprise in Xinjiang, with Xinjiang Commercial and Material Asset Management Co., Ltd. holding 51% of the shares, ultimately supervised by the Xinjiang State-owned Assets Supervision and Administration Commission. This change may affect the company's long-term strategy. Currently, there are no other significant announcements from the company, but investors are advised to pay attention to regular financial reports and any official disclosures regarding control dynamics [4].

证券日报网讯2月13日，百花医药（600721）在互动平台回答投资者提问时表示，2025年年审工作正在 进行中，2026年公司将不断强化在医药CRO及相关领域的竞争优势，积极优化业务布局，加强技术创 新，进一步加快客户拓展步伐，持续推进公司的高质量发展，具体情况请关注公司后续的定期报告。公 司指定的信息披露媒体为上海证券交易所网站及《上海证券报》《证券日报》，公司所有信息均以上述 指定媒体刊登的公告为准。请注意投资风险。 ...

证券日报网讯2月13日，百花医药（600721）在互动平台回答投资者提问时表示，关于公司2026年的经 营方向，还请关注公司拟定于2026年3月28日，即将披露的公司2025年年度报告。 ...

2026年2月5日 2026年2月3日，新疆百花村医药集团股份有限公司全资孙公司南京西默思博检测技术有限公司（以下简 称"西默思博"）收到江苏省科学技术厅、江苏省财政厅、国家税务总局江苏省税务局联合下发的《高新 技术企业证书》（证书编号：GR2025032009000），发证日期：2025年12月19日，有效期三年。西默思 博本次系第三次被认定为高新技术企业，根据《中华人民共和国企业所得税法》及国家对高新技术企业 的相关税收优惠政策规定，自2025年1月1日起连续三年（2025年-2027年）享受15%的企业所得税优惠 税率。 特此公告。 新疆百花村医药集团股份有限公司董事会 证券代码：600721 证券简称：百花医药 编号：2026-003 新疆百花村医药集团股份有限公司 关于全资孙公司获得高新技术企业证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ...

证券日报网讯 2月4日，百花医药发布公告称，公司全资孙公司南京西默思博检测技术有限公司收到江 苏省科学技术厅、江苏省财政厅、国家税务总局江苏省税务局联合下发的《高新技术企业证书》，西默 思博本次系第三次被认定为高新技术企业。 （文章来源：证券日报） ...

特此公告。 新疆百花村医药集团股份有限公司董事会 新疆百花村医药集团股份有限公司 2026 年 2 月 5 日 证券代码：600721 证券简称：百花医药 编号：2026-003 新疆百花村医药集团股份有限公司关于全资孙公司 获得高新技术企业证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026 年 2 月 3 日，新疆百花村医药集团股份有限公司全资孙公司南京西默 思博检测技术有限公司（以下简称"西默思博"）收到江苏省科学技术厅、江苏 省财政厅、国家税务总局江苏省税务局联合下发的《高新技术企业证书》（证书 编号：GR2025032009000），发证日期：2025 年 12 月 19 日，有效期三年。西 默思博本次系第三次被认定为高新技术企业，根据《中华人民共和国企业所得税 法》及国家对高新技术企业的相关税收优惠政策规定，自 2025 年 1 月 1 日起连 续三年（2025 年-2027 年）享受 15%的企业所得税优惠税率。 ...

格隆汇2月4日丨百花医药(600721.SH)公布，2026年2月3日，新疆百花村医药集团股份有限公司全资孙 公司南京西默思博检测技术有限公司（称"西默思博"）收到江苏省科学技术厅、江苏省财政厅、国家税 务总局江苏省税务局联合下发的《高新技术企业证书》（证书编号：GR2025032009000），发证日期： 2025年12月19日，有效期三年。西默思博本次系第三次被认定为高新技术企业。 ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

2025年10月28日公司发布的三季报数据显示，前三季度公司共实现营业收入2.99亿元，同比增长 2.74%，实现净利润3267.42万元，同比增长36.41%。（数据宝） 上交所公开信息显示，当日该股因日换手率达27.87%上榜，营业部席位合计净买入1925.72万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.53亿元，其中，买入成交额为8610.71 万元，卖出成交额为6684.99万元，合计净买入1925.72万元。 具体来看，今日上榜营业部中，第一大买入营业部为中信证券股份有限公司上海静安区山西北路证券营 业部，买入金额为2140.54万元，第一大卖出营业部为广发证券股份有限公司上海秀沿路证券营业部， 卖出金额为2007.02万元。 近半年该股累计上榜龙虎榜7次，上榜次日股价平均跌2.29%，上榜后5日平均涨0.46%。 资金流向方面，今日该股主力资金净流入1.63亿元，其中，特大单净流入1.34亿元，大单资金净流入 2892.65万元。近5日主力资金净流出8028.95万元。 百花医药(600721)今日涨停，全天换手率27.87%，成交额10.85亿元，振幅9.65%。龙虎榜数 ...

Market Overview - A-shares experienced a collective pullback on January 13, with the Shanghai Composite Index ending a 17-day winning streak, closing down 0.64% [1] - The total trading volume in the Shanghai and Shenzhen markets reached a historical high of 3.7 trillion [1] Sector Performance - Significant declines were observed in various sectors, including commercial aerospace, satellite internet, and military industries, with many stocks dropping over 8% [3] - The large aircraft and military sectors also faced downturns, with several stocks hitting the daily limit down [3] - The commercial aerospace index fell by 6.15%, with a net outflow of 230.78 billion [4] Individual Stock Movements - Over 1,600 stocks rose, with more than 70 stocks hitting the daily limit up, while the commercial aerospace sector saw over 60 stocks limit down or drop more than 10% [3] - Specific stocks such as Aerospace Electronics and Beidou Star Communication experienced significant declines, with many stocks in the sector down by nearly 10% [7] Investment Insights - Analysts suggest that the current market sentiment may indicate a nearing peak, with potential for further structural upward trends despite short-term volatility [12] - Key investment strategies include avoiding speculative risks in popular sectors, focusing on policy-driven industries, and maintaining diversified portfolios to balance risk and return [14] - The emphasis is on sectors with strong earnings growth and valuation alignment, particularly in technology manufacturing and innovative healthcare [14]